The paper highlights many successful results in vitro and in animal models, but there is not enough discussion about why these promising delivery systems still did not go to clinical stage. For example, the authors mention that as of late 2024, no PROTAC with nanocarrier or prodrug strategy has FDA IND approval, but they don’t explain clearly what are the main barriers. Maybe it is about difficulty in large-scale production, or immune reaction in human, or maybe cost and regulatory complications. Also, how stable these systems are in real human blood and how efficiently they reach solid tumors is not discussed. I think it would be more helpful if authors give some critical analysis of these issues, because it can explain better why the translation from lab to clinic is still very slow, even after many technical innovations.